Effectiveness and Cost-Effectiveness of Human Papillomavirus Vaccination Through Age 45 Years in the United States

Annals of Internal Medicine
7 January 2020 Vol: 172, Issue 1
http://annals.org/aim/issue

 

Editorials
Effectiveness and Cost-Effectiveness of Human Papillomavirus Vaccination Through Age 45 Years in the United States
Jean-François Laprise, PhD; Harrell W. Chesson, PhD; Lauri E. Markowitz, MD; Mélanie Drolet, PhD; Dave Martin, PhD; Élodie Bénard, MSc; Marc Brisson, PhD
Results of Base-Case Analysis:
The model predicts that the current U.S. HPV vaccination program will reduce the number of diagnoses of anogenital warts and cervical intraepithelial neoplasia of grade 2 or 3 and cases of cervical cancer and noncervical HPV-associated cancer by 82%, 80%, 59%, and 39%, respectively, over 100 years and is cost saving (vs. no vaccination). In contrast, extending vaccination to women and men aged 45 years is predicted to reduce these outcomes by an additional 0.4, 0.4, 0.2, and 0.2 percentage points, respectively. Vaccinating women and men up to age 30, 40, and 45 years is predicted to cost $830,000, $1,843,000, and $1,471,000, respectively, per quality-adjusted life-year gained (vs. current vaccination).